Appendix 2 (as supplied by the authors): Included and excluded studies

A. Included studies

1. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. *Cochrane Database of Systematic Reviews.* 2010.
2. Bona DD, Plaia A, Leto-Barone MS, Piana SL, Lorenzo GD. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: a systematic review and meta-analysis. *JAMA Intern Med.* 2015;175:1301.
3. Bousquet PJ, Calder. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. *J Allergy Clin Immunol.* 2011;127:49-56; Randomized trials provide evidence to inform treatment decisions. The Consolidated Standards of Reporting Trials (CONSORT) Statement is a set of recommendations for the reporting of trials.
4. CADTH. Timothy grass standardized allergenic extract (Grastek - Merck Canada Inc.) indication: allergic rhinitis (grass pollen). 2014.
5. Calderon M, Mosges R, Hellmich M, Demoly P. Towards evidence-based medicine in specific grass pollen immunotherapy. *Allergy.* 2010;65:420.
6. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. *The Cochrane database of systematic reviews.* 2007:Cd001936.
7. Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. *J Allergy Clin Immunol.* 2013;132:1322.
8. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. *Cochrane Database of Systematic Reviews.* 2011.
9. Chelladurai Y, Suarez-Cuervo C, Erekosima N, et al. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. *J Allergy Clin Immunol Pract.* 2013;1:361.
10. Creticos PS, Bernstein DI, Casale TB, Lockey RF, Maloney J, Nolte H. Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review. *J Allergy Clin Immunol Pract.* 2016;4:1194.
11. Cui XT. Dust mite sublingual immunotherapy for allergic rhinitis: A meta-analysis. *Chinese Journal of Evidence-Based Medicine.* 2013;13:885.
12. Devillier P, Dreyfus JF, Demoly P, Calderon MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. 2014;12:71.
13. Dhami S, Nurmatov U, Agache I, et al. Allergen immunotherapy for allergic asthma: protocol for a systematic review. *Clin Transl Allergy.* 2015;6:5.
14. Dhami S, Nurmatov U, Roberts G, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review. *Clin Transl Allergy.* 2016;6:12.
15. Dranitsaris G, Ellis AK. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost. *J Eval Clin Pract.* 2014;20:225.
16. Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. *J Allergy Clin Immunol.* 2013;131:1361.
17. Editorial Board of Chinese Journal of Otorhinolaryngology H, Neck Surgery Subspecialty Group of R, Society of Otorhinolaryngology H, Neck Surgery Subspecialty Group of R. Expert consensus on allergen specific immunotherapy of allergic rhinitis. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.* 2011;46:976.
18. Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. *Laryngoscope.* 2014;124:616.
19. Feng S, Xu Y, Ma R, Sun Y, Luo X, Li H. Cluster subcutaneous allergen specific immunotherapy for the treatment of allergic rhinitis: a systematic review and meta-analysis. *PLoS ONE [Electronic Resource].* 2014;9:e86529.
20. Kim JM, Lin SY, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. *Pediatrics.* 2013;131:1155.

Appendix to: Elliott J, Kelly S, Johnston A, et al. Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella review. *CMAJ Open* 2017. DOI:10.9778/cmajo.20160066.

21. Klimek L, Willers J, Schendzielorz P, Kundig TM, Senti G. Immunotherapy of allergic rhinitis without allergens? : new options for immunomodulation by vaccination with virus-like particles and CpG motifs. *HNO*. 2013;61:826.
22. Klimek LW. Authorized diagnostic test allergens for intracutaneous testing are no longer available in Germany. Allergological textbooks need to be rewritten. *Allergologie*. 2015;38:141.
23. Kopp MV, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen F. The revised guideline on Primary Allergy Prevention. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2012;55:338.
24. Kopp MVB. Specific immunotherapy in childhood: Subcutaneous or sublingual administration. *Monatsschr Kinderheilkd*. 2013;161:616.
25. Larenas-Linnemann D, Blaiss M, Bever HPV, Compalati E, Baena-Cagnani CE. Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. *Ann Allergy Asthma Immunol*. 2013;110:402.
26. Larenas-Linnemann D, Mayorga-Butron JL, Sanchez-Gonzalez A, et al. ARIA Mexico 2014. Adaptation of the Clinical Practice Guide ARIA 2010 for Mexico. Methodology ADAPTE. *Rev Alerg Mex*. 2014;61 Suppl 1:S3.
27. Larenas-Linnemann DE, Pietropaolo-Cienfuegos DR, Calderon MA. Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward. *Ann Allergy Asthma Immunol*. 2011;107:407.
28. Liao W, Hu Q, Shen LL, et al. Sublingual Immunotherapy for Asthmatic Children Sensitized to House Dust Mite: A Meta-Analysis. *Medicine*. 2015;94:e701.
29. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. *JAMA : the journal of the American Medical Association*. 2013;309:1278.
30. Lin SY, Erekosima N, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for the treatment of allergic rhinoconjunctivitis and/or asthma: comparative effectiveness review. 2013.
31. Lu Y, Xu L, Xia M, Li Y, Cao L. The efficacy and safety of subcutaneous immunotherapy in mite-sensitized subjects with asthma: a meta-analysis. *Respiratory Care*. 2015;60:269.
32. Manzotti G, Lombardi C. Allergen immunotherapy as a drug: the new deal of grass allergen tablets from clinical trials to current practice. *Eur Ann Allergy Clin Immunol*. 2013;45:34.
33. Maslany AJ. Allergen-specific immunotherapy in children. *Pediatria i Medycyna Rodzinna*. 2011;7:212.
34. Meadows A, Kaambwa B, Novielli N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. *Health Technol Assess*. 2013;17:1.
35. Normansell R, Kew KM, Bridgman AL. Sublingual immunotherapy for asthma. *Cochrane Database of Systematic Reviews*. 2015;8:CD011293, 2015.
36. Ott H, Bufe A, Merk HF. Indications and evidence base for specific immunotherapy in childhood. *Hautarzt*. 2011;62:671.
37. Purkey MT, Smith TL, Ferguson BJ, et al. Subcutaneous immunotherapy for allergic rhinitis: an evidence based review of the recent literature with recommendations. *Int Forum Allergy Rhinol*. 2013;3:519.
38. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. *Cochrane Database of Systematic Reviews*. 2010.
39. Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: Allergic rhinitis. *Otolaryngol Head Neck Surg*. 2015;152:S1.
40. Tao L, Shi B, Shi G, Wan H. Efficacy of sublingual immunotherapy for allergic asthma: retrospective meta-analysis of randomized, double-blind and placebo-controlled trials. *Clin Respir J*. 2014;8:192.
41. Wilson D, Torres-Lima M, Durham S. Sublingual immunotherapy for allergic rhinitis. 2011.
42. Wu YY, Xie XM, Han D, Li SJ, Liu L, Li MX. A Meta-analysis of efficacy and safety of sublingual immunotherapy on allergic asthma. *Chung Hua Nei Ko Tsa Chih*. 2013;52:844.
43. Yang Y, Zhou W, Chen A. Efficacy of sublingual immunotherapy for cedar pollinosis: A systematic review and meta-analysis. *Ann Allergy Asthma Immunol*. 2016;117:348.
44. Zhang QY. Efficacy and safety of dust mite sublingual immunotherapy for pediatric allergic rhinitis: A meta-analysis. *Chinese Journal of Evidence-Based Medicine*. 2014;14:1373.

Foreign articles not translated

1. Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery Subspecialty Group of Rhinology,Society of Otorhinolaryngology Head and Neck Surgery Subspecialty Group of Rhinology. Expert consensus on allergen specific immunotherapy of allergic rhinitis. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.* 2011;46:976.
2. Jung A. Maslany. Allergen-specific immunotherapy in children. *Pediatria i Medycyna Rodzinna.* 2011;7:212.
3. Klimek L, Willers J, Schendzielorz P, Kundig TM, Senti G. Immunotherapy of allergic rhinitis without allergens? : new options for immunomodulation by vaccination with virus-like particles and CpG motifs. *HNO.* 2013;61:826.
4. Kopp MV. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. The revised guideline on Primary Allergy Prevention. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2012;55:338.
5. Kopp MVB. Specific immunotherapy in childhood: Subcutaneous or sublingual administration. *Monatsschrift fur Kinderheilkunde.* 2013;161:616.
6. Larenas-Linnemann D, Mayorga-Butron JL, Sanchez-Gonzalez A, et al. Adaptation of the Clinical Practice Guide ARIA 2010 for Mexico. Methodology ADAPTE. *Rev Alerg Mex.* 2014;61(Suppl 1):S3.
7. Ott H, Bufe A, Merk HF. Indications and evidence base for specific immunotherapy in childhood. *Hautarzt.* 2011;62:671.
8. Tian Cui X. Dust mite sublingual immunotherapy for allergic rhinitis: A meta-analysis. *Chinese Journal of Evidence-Based Medicine.* 2013;13:885.
9. Werfel Klimek L. Authorized diagnostic test allergens for intracutaneous testing are no longer available in Germany. Allergological textbooks need to be rewritten. *Allergologie.* 2015;38:141.
10. Wu Y, Xie XM, Han D, et al. A Meta-analysis of efficacy and safety of sublingual immunotherapy on allergic asthma. *Chung Hua Nei Ko Tsa Chih.* 2013;52:844.
11. Yasin Q.Zhang. Efficacy and safety of dust mite sublingual immunotherapy for pediatric allergic rhinitis: A meta-analysis. *Chinese Journal of Evidence-Based Medicine.* 2014;14:1373.

B. Excluded studies

1. Longer follow-up, but still no proven advantage. *Prescrire International.* 2010;19:273.
2. Timothy pollen. Longer follow-up, but still no proven advantage. *Prescrire International.* 2010;19:273.
3. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: A systematic review (JAMA - Journal of the American Medical Association (2013) 309, 12 (1278-1288) DOI:10.1001/jama.2013.2049) [erratum]. *JAMA : the journal of the American Medical Association.* 2013;310:647.
4. Aasbjerg K, Dalhoff KP, Backer V. Adverse Events During Immunotherapy Against Grass Pollen-Induced Allergic Rhinitis - Differences Between Subcutaneous and Sublingual Treatment. *Basic Clin Pharmacol Toxicol.* 2015;117:73.
5. Aboshady OA, Elghanam KM. Sublingual immunotherapy in allergic rhinitis: efficacy, safety, adherence and guidelines. 2014;7:241.
6. Almarales RLC. Therapeutic effect and safety of the sublingual immunotherapy with tropical house dust mite allergen vaccines in asthmatic cuban adult patients. *World Allergy Organization Journal.* 2012;Conference:February.
7. Alzakar RH, Alsamarai AM. Efficacy of immunotherapy for treatment of allergic asthma in children. *Allergy and Asthma Proceedings.* 2010;31:324.
8. Ameille J, Didier A, Serrano E, et al. Recommendations for the prevention and management of occupational allergic rhinitis. Societe francaise de medecine du travail. Societe de pneumologie de langue francaise. Societe francaise d'allergologie. Societe francaise d'oto-rhino-laryngologie et de chirurgie de la face et du cou. *Rev Mal Respir.* 2011;28:940.
9. Arasi S, Passalacqua G, Caminiti L, Crisafulli G, Fiamingo C, Pajno GB. Efficacy and safety of sublingual immunotherapy in children. 2016;12:49.
10. Bachert C. Effectiveness of preparations with non-modified allergens for sublingual application - Evaluation of evidence by reference to clinical trials. *Allergologie.* 2012;35:59.

11. Bachert CD. Efficacy of non-modified allergen products for subcutaneous specific immunotherapy - Evaluation of evidence in clinical trials. *Allergologie*. 2010;33:379.
12. Baena-Cagnani CE, Larenas-Linnemann D, Teijeiro A, Canonica GW, Passalacqua G. Will sublingual immunotherapy offer benefit for asthma? *Curr Allergy Asthma Rep*. 2013;13:571.
13. Bahceciler NN, Cobanoglu N. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma. *Immunotherapy*. 2011;3:747.
14. Bahceciler NN, Galip N, Cobanoglu N. Multiallergen-specific immunotherapy in polysensitized patients: where are we? *Immunotherapy*. 2013;5:183.
15. Bahceciler NNH. A milestone in house dust-mite-allergen immunotherapy: The new sublingual tablet S-524101 (actair). *Expert Rev Vaccines*. 2014;13:1427.
16. Barone MSDL. Subcutaneus vs sublingual immunotherapy. *Allergy: European Journal of Allergy and Clinical Immunology*. 2013;Conference:September.
17. Barr JGA. Allergic rhinitis in children. *BMJ (Online)*. 4153;349:g4153.
18. Biagtan M, Viswanathan R, Bush RK. Immunotherapy for house dust mite sensitivity: where are the knowledge gaps? *Curr Allergy Asthma Rep*. 2014;14:482.
19. Bilo MBA. Honeybee venom immunotherapy: certainties and pitfalls. *Immunotherapy*. 2012;4:1153.
20. Blake K, Raissy H. Updated Guidelines on Allergic Rhinitis - Anything New? *Pediatric, Allergy, Immunology, and Pulmonology*. 2015;28:129.
21. Bona DD, Plaia A, Barone MSL, et al. Efficacy of grass pollen allergen syblingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis. A systematic review and meta-analysis. *Allergy: European Journal of Allergy and Clinical Immunology.Conference: 35th Annual Congress of the European Academy of Allergy and Clinical Immunology, EAACI 2016.Austria.Conference Start: 20160611.Conference End: 20160615.71 ()(pp 616-617), 2016*. 2016:616.
22. Bona DD, Plaia A, Leto-Barone MS, Piana SL, Lorenzo GD. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. *J Allergy Clin Immunol*. 2012;130:1097.
23. Bona DD, Plaia A, Scafidi V, Leto-Barone MS, Lorenzo GD. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. *J Allergy Clin Immunol*. 2010;126:558.
24. Bona DSD. Sublingual immunotherapy with natural grass pollen extracts: An appraisal of the evidence. *Therapy*. 2011;8:443.
25. Bot CMd, Moed H, Berger MY, Roder E, Wijk RGv, Wouden JCvd. Sublingual immunotherapy in children with allergic rhinitis: quality of systematic reviews. *Pediatr Allergy Immunol*. 2011;22:548.
26. Bowry P. A systematic review of randomised controlled trials, non-randomised controlled trials and observational studies to ascertain the role of pollen-specific immunotherapy in improving clinical outcomes in pollen-food (ORAL ALLERGY) syndrome. *World Allergy Organization Journal.Conference: 3rd WAO International Scientific Conference, WISC 2014.Rio de Janeiro Brazil.Conference Start: 20141206.Conference End: 20141209.Conference Publication: (var.pagings).8 (no pagination), 2015.Date of Pu*. 2015.
27. Boyle RE. Venom immunotherapy for preventing allergic reactions to insect stings: A systematic review and health economic analysis. *Allergy: European Journal of Allergy and Clinical Immunology*. 2012;Conference:November.
28. Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. *Cochrane Database of Systematic Reviews*. 2012;10:CD008838, 2012.
29. Brehler R, Klimek L, Kopp MV, Virchow JC. Specific immunotherapy-indications and mode of action. *Dtsch Artzebl Int*. 2013;110:148.
30. Brown TCT. The sting of the honeybee: an allergic perspective. *Annals of Allergy, Asthma and Immunology*. 2011;107:463.
31. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. *J Allergy Clin Immunol*. 2010;126:466.
32. Bryson R. Sublingual immunotherapy for grass pollen allergy in children: A systematic review and meta-analysis. *World Allergy Organization Journal*. 2012;Conference:February.
33. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. *J Allergy Clin Immunol*. 2013;131:1288.

34. Burton MJK. Extracts from The Cochrane Library: Sublingual immunotherapy for Allergic Rhinitis. *Otolaryngol Head Neck Surg.* 2011;144:149.
35. Calderon MA, Bernstein DI, Blaiss M, Andersen JS, Nolte H. A comparative analysis of symptom and medication scoring methods used in clinical trials of sublingual immunotherapy for seasonal allergic rhinitis. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.* 2014;44:1228.
36. Calderon MA, Boyle RJ, Penagos M, Sheikh A. Immunotherapy: The meta-analyses. What have we Learned? *Immunol Allergy Clin North Am.* 2011;31:159.
37. Calderon MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. *J Allergy Clin Immunol.* 2011;127:30.
38. Calderon MA, Eichel A, Makatsori M, Pfaar O. Comparability of subcutaneous and sublingual immunotherapy outcomes in allergic rhinitis clinical trials. *Current Opinion in Allergy and Clinical Immunology.* 2012;12:249.
39. Calderon MA, Kleine-Tebbe J, Linneberg A, et al. House Dust Mite Respiratory Allergy: An Overview of Current Therapeutic Strategies. *Journal of Allergy and Clinical Immunology: In Practice.* 2015;3:843.
40. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.* 2011;41:1263.
41. Calderon MA, Rio PRD, Vidal C, et al. An EAACI "European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)": the methodology. *Clin Transl Allergy.* 2014;4:22, 2014.
42. Calderon MAG. Perspectives on allergen-specific immunotherapy in childhood: An EAACI position statement. *Pediatric Allergy and Immunology.* 2012;23:300.
43. Calderon MAP. Allergen injection immunotherapy for perennial allergic rhinitis: A Cochrane systematic review and meta-analysis. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.* 2013;Conference:1431.
44. Calderon MAP. Allergen injection immunotherapy for perennial allergic rhinitis: Cochrane systematic review and meta-analysis. *Allergy: European Journal of Allergy and Clinical Immunology.* 2013;Conference:September.
45. Calderon MAR. Sublingual allergen immunotherapy in children: An evidence-based overview. *Revue Francaise d'Allergologie.* 2012;52:20.
46. Calderon MM. From evidence-based medicine to practice in specific grass pollen immunotherapy of seasonal allergic rhinoconjunctivitis. *J Allergy Clin Immunol.* 2010;Conference:AB123.
47. Calderon MSA. Meta-analysis supports that the efficacy of grass allergy immunotherapy tablets is comparable to subcutaneous immunotherapy. *Allergy: European Journal of Allergy and Clinical Immunology.* 2011;Conference:June.
48. Caminati M, Dama A, Schiappoli M, Senna G. Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? *Expert Review of Clinical Immunology.* 2013;9:937.
49. Canonica GWC. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. *World Allergy Organization Journal.* 2014;7.
50. Chelladurai Y, Lin SY. Effectiveness of subcutaneous versus sublingual immunotherapy for allergic rhinitis: current update. *Current Opinion in Otolaryngology and Head and Neck Surgery.* 2014;22:211.
51. Cingi C, Muluk NB, Hanci D, Ulusoy S, Sahin F. Updating the role played by immunotherapy for allergic rhinitis: meta-analysis. *Int Forum Allergy Rhinol.* 2015;5:132.
52. Compalati E, Braido F, Canonica GW. Sublingual immunotherapy: recent advances. 2013;62:415.
53. Compalati E, Braido F, Canonica GW. An update on allergen immunotherapy and asthma. *Current Opinion in Pulmonary Medicine.* 2014;20:109.
54. Compalati E, Mistrello G. The relative clinical impact of sublingual immunotherapy with carbamylated monomeric allergoids on allergic respiratory symptoms. *World Allergy Organization Journal.Conference: 3rd WAO International Scientific Conference, WISC 2014.Rio de Janeiro Brazil.Conference Start: 20141206.Conference End: 20141209.Conference Publication: (var.pagings).8 (no pagination), 2015.Date of Pu.* 2015.
55. Compalati EB. Sublingual immunotherapy: recent advances. *Allergology International.* 2013;62:415.
56. Cox L. Sublingual immunotherapy for aeroallergens: status in the United States. *Allergy and Asthma Proceedings.* 2014;35:34.

57. Cox L. Allergy immunotherapy in reducing healthcare cost. *Current Opinion in Otolaryngology and Head and Neck Surgery.* 2015;23:247.
58. Cox L. The role of allergen immunotherapy in the management of allergic rhinitis. *Am J Rhinol Allergy.* 2016;30:48.
59. Cox L, Calderon M, Pfaar O. Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations. *Immunotherapy.* 2012;4:601.
60. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. *J Allergy Clin Immunol.* 2011;127:S1.
61. Creticos P, Durham S, Kaur A, et al. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal allergic rhinitis: Analysis of clinical trials. *Annals of Allergy, Asthma and Immunology.Conference: 2015 Annual Meeting of the American College of Allergy, Asthma and Immunology.San Antonio, TX United States.Conference Start: 20151105.Conference End: 20151109.Conference Publication: (var.pagings).* 2015:A29.
62. Creticos PS, Bernstein DI, Casale TB, Lockey RF, Nolte H. Co-seasonal initiation of allergen immunotherapy: A systematic review. *Journal of Allergy and Clinical Immunology.Conference: 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, AAAAI 2016.Los Angeles, CA United States.Conference Start: 20160304.Conference End: 20160307.Conference Publication:.* 2016:AB264.
63. Creticos PS, Durham S, Nelson HS, et al. Comparison of relative and absolute treatment differences between sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses of clinical trials. *Allergy: European Journal of Allergy and Clinical Immunology.Conference: 35th Annual Congress of the European Academy of Allergy and Clinical Immunology, EAACI 2016.Austria.Conference Start: 20160611.Conference End: 20160615.71 ()(pp 29), 2016.Date.* 2016:29.
64. Davila I, Navarro A, Dominguez-Ortega J, et al. SLIT: indications, follow-up, and management. *J Investig Allergol Clin Immunol.* 2014;24 Suppl 1:1.
65. Demoly PJ. Cross-reactivity and allergic rhinoconjunctivitis: Practical implications for immunotherapy with a timothy grass pollen tablet. *Revue Francaise d'Allergologie.* 2012;52:388.
66. Devillier P. Allergic rhinitis treatment with sublingual immunotherapy. *J Pediatr.* 2015;167:1172.
67. Devillier PB. The clinical development of specific immunotherapies: Specific methodological issues and clinical interpretation of results. *Allergy: European Journal of Allergy and Clinical Immunology.* 2010;Conference:June.
68. Devillier PD. An evaluation of data on the relative clinical impact of sublingual allergen immunotherapy tablets and symptomatic medications in grass-pollen-induced allergic rhinoconjunctivitis. *Allergy: European Journal of Allergy and Clinical Immunology.* 2013;Conference:September.
69. Devillier PD. A comparison of the relative clinical impacts of sublingual allergen immunotherapy tablets and symptomatic drugs in grass-pollen-induced allergic rhinoconjunctivitis. *Allergy: European Journal of Allergy and Clinical Immunology.* 2014;Conference:September.
70. DeYoung K, Wentzel JL, Schlosser RJ, Nguyen SA, Soler ZM. Systematic review of immunotherapy for chronic rhinosinusitis. *Am J Rhinol Allergy.* 2014;28:145.
71. Durham SR, Creticos PS, Nelson HS, et al. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses. *J Allergy Clin Immunol.* 2016;138:1081.
72. Durham SR, Nelson HS, Nolte H, et al. Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. *Allergy.* 2014;69:617.
73. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? *J Allergy Clin Immunol.* 2016;137:339.
74. Duric-Filipovic I, Caminati M, Kostic G, Filipovic D, Zivkovic Z. Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis. *World Journal of Pediatrics.* 2016;12:283.
75. Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. *Expert Opin Biol Ther.* 2013;13:1543.
76. Fernndez-Tvora LJ. Safety evaluation of rapid build-up schedules with IR-standardized allergen extracts for subcutaneous immunotherapy of allergic respiratory diseases. *Expert Opin Drug Saf.* 2011;10:947.
77. Finegold I, Dockhorn RJ, Ein D, Dolen WK, Oppenheimer J, Potter LH. Immunotherapy throughout the decades: from Noon to now. *Ann Allergy Asthma Immunol.* 2010;105:328.

78. Frati F, Incorvaia C, David M, et al. Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy. *Drug design, development & therapy.* 2012;6:117.
79. Frati F, Incorvaia C, Lombardi C, Senna G. Allergen immunotherapy: 100 years, but it does not look like. *Eur Ann Allergy Clin Immunol.* 2012;44:99.
80. Fujimura T, Okamoto Y, Taniguchi M. Therapeutic effects and biomarkers in sublingual immunotherapy: a review. *J Allergy (Cairo).* 2012;2012:381737.
81. Fujisawa T. ALLERGEN IMMUNOTHERAPY IN CHILDREN. *Arerugi.* 2015;64:787.
82. Gan EC, Thamboo A, Rudmik L, Hwang PH, Ferguson BJ, Javer AR. Medical management of allergic fungal rhinosinusitis following endoscopic sinus surgery: an evidence-based review and recommendations. *Int Forum Allergy Rhinol.* 2014;4:702.
83. Garani VD. Pharmacoeconomic assessment of the use of a depigmented polymerised allergen extract in comparison to symptomatic treatment in patients with allergic rhinitis. *Allergy: European Journal of Allergy and Clinical Immunology.* 2014;Conference:September.
84. Garbo GT. Complementary and Integrative Treatments: Allergy. *Otolaryngol Clin North Am.* 2013;46:295.
85. Gentile DB. Current and Future Directions in Pediatric Allergic Rhinitis. *Journal of Allergy and Clinical Immunology: In Practice.* 2013;1:214.
86. Goksel OM. Allergen specific immunotherapy studies in Turkey: Results of a systematic review with meta-analysis. *Allergy: European Journal of Allergy and Clinical Immunology.* 2010;Conference:June.
87. Goldsobel A. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: A systematic review. *Pediatrics.* 2013;132:S49.
88. Gomez MJ, Cabrerizo S. Clinical evolution of patients treated with a precoseasonal sublingual immunotherapy with a native extract of grass pollen. *Allergy: European Journal of Allergy and Clinical Immunology.Conference: 35th Annual Congress of the European Academy of Allergy and Clinical Immunology, EAACI 2016.Austria.Conference Start: 20160611.Conference End: 20160615.71 ()(pp 332-333), 2016.* 2016:332.
89. Graf N, Dinkel B, Rose H, et al. A critical appraisal of analyzing nasal provocation test results in allergen immunotherapy trials. *Rhinology.* 2014;52:137.
90. Greenhaw B, deShazo RD, Arnold J, Wright L. Fungal immunotherapy in patients with allergic fungal sinusitis. *Ann Allergy Asthma Immunol.* 2011;107:432.
91. Hagen A, Gorenoi V, Schonermark MP. Specific immunotherapy (SIT) in the treatment of allergic rhinitis. *GMS Health Technology Assessment.* 2010;6:Doc01, 2010.
92. Hamelmann E, Pfaar O, Bona DD, et al. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis - a systematic review and meta-analysis. *Allergologie.* 2015;38:616.
93. Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? *Current Opinion in Allergy and Clinical Immunology.* 2014;14:363.
94. Hockenhull J, Elremeli M, Cherry MG, et al. A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen for the treatment of bee and wasp venom allergy. *Health Technol Assess.* 2012;16:1.
95. Incorvaia C, Frati F. One century of allergen-specific immunotherapy for respiratory allergy. *Immunotherapy.* 2011;3:629.
96. Incorvaia C, Frati F, Dell'Albani I, et al. Safety of hymenoptera venom immunotherapy: a systematic review. *Expert Opin Pharmacother.* 2011;12:2527.
97. Incorvaia C, Fuiano N, Leo G. Sublingual immunotherapy for treating respiratory allergy: a review on its effectiveness and suitability. *Clin Ter.* 2010;161:543.
98. Incorvaia C, Masieri S, Berto P, Scurati S, Frati F. Specific immunotherapy by the sublingual route for respiratory allergy. *Allergy Asthma Clin Immunol.* 2010;6:29, 2010.
99. Incorvaia C, Masieri S, Scurati S, Soffia S, Puccinelli P, Frati F. The current role of sublingual immunotherapy in the treatment of allergic rhinitis in adults and children. *J Asthma Allergy.* 2011;4:13.
100. Incorvaia C, Mauro M, Ridolo E. Sublingual immunotherapy for allergic rhinitis: where are we now? *Immunotherapy.* 2015;7:1105.
101. Incorvaia C, Riario-Sforza GG, Incorvaia S, Frati F. Sublingual immunotherapy in allergic asthma: Current evidence and needs to meet. *Ann Thorac Med.* 2010;5:128.
102. Incorvaia C, Rienzo AD, Celani C, Makri E, Frati F. Treating allergic rhinitis by sublingual immunotherapy: a review. *Ann Ist Super Sanita.* 2012;48:172.

103. Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. *J Allergy Clin Immunol*. 2015;136:556.
104. Jutel M, Bartkowiak-Emeryk M, Breborowicz A, et al. Sublingual immunotherapy (SLIT) - Indications, mechanism, and efficacy: Position paper prepared by the section of immunotherapy, polish society of allergy. *Annals of Agricultural and Environmental Medicine*. 2016;23:44.
105. Kaluzinska-Parzyszek IM. Sublingual immunotherapy is effective and safe in children. *Alergia Astma Immunologia*. 2011;16:139.
106. Kariyawasam HK, Rotiroti G, Robinson DS. Sublingual immunotherapy in allergic rhinitis: indications, efficacy and safety. *Rhinology*. 2013;51:9.
107. Kettner JL. A high-dose hypoallergenic house dust mite preparation improves lung function parameters in rhinoconjunctivitis patients with bronchial hyperreactivity. *Allergy: European Journal of Allergy and Clinical Immunology*. 2011;Conference:June.
108. Kleine-Tebbe JB. Specific immunotherapy (hyposensitization) for IgE-mediated allergic diseases. *Allergologie*. 2010;33:3.
109. Klimek LP. A comparison of immunotherapy delivery methods for allergen immunotherapy. *Expert Review of Clinical Immunology*. 2013;9:465.
110. Krishna MT, Ewan PW, Diwakar L, et al. Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology*. 2011;41:1201.
111. Labrada AM. IgE/IgG4 ratio as a possible surrogate marker of clinical efficacy during allergen-specific immunotherapy with house dust mite vaccines. *World Allergy Organization Journal*. 2012;Conference:February.
112. Larenas-Linnemann D. How does the efficacy and safety of Oralair compare to other products on the market? *Therapeutics and Clinical Risk Management*. 2016;12:831.
113. Larsen JN, Broge L, Jacobi H. Allergy immunotherapy: The future of allergy treatment. *Drug Discovery Today*. 2016;21:26.
114. Leatherman BD, Khalid A, Lee S, et al. Dosing of sublingual immunotherapy for allergic rhinitis: evidence-based review with recommendations. *Int Forum Allergy Rhinol*. 2015;5:773.
115. Lee J, Park CO, Lee KH. Specific immunotherapy in atopic dermatitis. *Allergy Asthma Immunol Res*. 2015;7:221.
116. Lee ML. Sublingual immunotherapy for house dust mite allergy in Southeast Asian children. *Asian Pacific Journal of Allergy and Immunology*. 2013;31:190.
117. Lee S, Nolte H, Benninger MS. Clinical considerations in the use of sublingual immunotherapy for allergic rhinitis. *Am J Rhinol Allergy*. 2015;29:106.
118. Lester MR. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis-based comparison. *Pediatrics*. 2013;132:S48.
119. Lierl MB. New developments in the treatment of pediatric allergic rhinitis and conjunctivitis. *Pediatr.Ann*. 2014;43:e192.
120. Lim MY, Leong JL. Allergic rhinitis: evidence-based practice. *Singapore Med J*. 2010;51:542.
121. Lin SY. Sublingual immunotherapy: current concepts for the U.S. practitioner. *Int Forum Allergy Rhinol*. 2014;4 Suppl 2:S55.
122. Lin SYL. Sublingual Immunotherapy. *Otolaryngol Clin North Am*. 2011;44:753.
123. Mantelli F, Lambiase A, Bonini S, Bonin S. Clinical trials in allergic conjunctivits: a systematic review. *Allergy*. 2011;66:919-24.
124. Masuyama K, Goto M, Takeno S, et al. Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients. *Auris Nasus Larynx*. 2016;43:1.
125. Matricardi PM, Kuna P, Panetta V, Wahn U, Narkus A. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. *J Allergy Clin Immunol*. 2011;128:791.
126. Matricardi PMK. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: A comparison based on meta-analyses. *J Allergy Clin Immunol*. 2011;Conference:AB218.
127. Mener DJ, Lin SY. The role of allergy immunotherapy in the treatment of asthma. 2016;24:215.
128. Migueres MDB. Hay fever: Why use the sublingual route for desensitisation? *Prescrire International*. 2012;21:24.

129. Mosges R, Ritter B, Kayoko G, Allekotte S. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais tablets. *Acta Dermatovenerologica Alpina, Pannonica et Adriatica.* 2010;19:3.
130. Mosges RK. Carbamylated monoid allergoids as a new therapeutic option for sublingual immunotherapy of mite- and grass-induced allergic rhinoconjunctivitis - A systematic review of published trials using Lais tablets. *Allergo Journal.* 2010;19:342.
131. Mosges RR. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: A systematic review of published trials with a meta-analysis of treatment using Laid tablets (Acta Dermatovenerologica Alpina, Pannonica et Adriatica (2010) 19, 3 (3-10)). *Acta Dermatovenerologica Alpina, Pannonica et Adriatica.* 2010;19:35.
132. Mullins RJ, Brown SG. Ant venom immunotherapy in Australia: the unmet need. *Med J Aust.* 2014;201:33.
133. Najib MW. Impact of allergen immunotherapy on quality of life and health care costs in adults and children with grass pollen-induced allergic rhinitis in Germany. *Value in Health.* 2014;Conference:A597.
134. Najib MW. Impact of allergen immunotherapy on symptom-free days and health care costs in patients with grass pollen-induced allergic rhinitis in Germany. *Value in Health.* 2014;Conference:A597.
135. Najib MW. Impact of allergen immunotherapy on quality of life and healthcare costs in adults and children with grass polleninduced allergic rhinitis in Germany. *Allergy: European Journal of Allergy and Clinical Immunology.* 2014;Conference:September.
136. Najib MW. Impact of allergen immunotherapy on symptom-free days and healthcare costs in patients with grass pollen-induced allergic rhinitis in Germany. *Allergy: European Journal of Allergy and Clinical Immunology.* 2014;Conference:September.
137. Nelson H, Cartier S, Allen-Ramey F, Lawton S, Calderon MA. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy. *J Allergy Clin Immunol Pract.* 2015;3:256.
138. Nelson HC. Meta-analysis of allergen immunotherapy for treatment of grass pollen allergies indicates sublingual immunotherapy tablet is comparable to subcutaneous immunotherapy. *Allergy: European Journal of Allergy and Clinical Immunology.* 2013;Conference:September.
139. Nelson HS. Update on house dust mite immunotherapy: are more studies needed? *Current Opinion in Allergy and Clinical Immunology.* 2014;14:542.
140. Nelson HS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? *J Allergy Clin Immunol Pract.* 2014;2:144.
141. Nelson HS. Oral/sublingual phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA. *Expert Review of Clinical Immunology.* 2014;10:1437.
142. Nelson HS. New forms of allergy immunotherapy for rhinitis and asthma. *Allergy and Asthma Proceedings.* 2014;35:271.
143. Nieto AC. Meta-analysis on immunotherapy with depigmented glutaraldehyde-polymerized extracts. *Allergy: European Journal of Allergy and Clinical Immunology.* 2012;Conference:November.
144. Nihr HSC. House dust mite allergen immunotherapy tablet (Mitizax) for house dust mite allergy-induced rhinitis and conjunctivitis ? third line. 2013.
145. Okubo K, Gotoh M. Allergen immunotherapy for allergic rhinitis. *J Nippon Med Sch.* 2010;77:285.
146. Ozdemir C. Monoclonal antibodies in allergy; Updated applications and promising trials. *Recent Patents on Inflammation and Allergy Drug Discovery.* 2015;9:54.
147. Ozdemir O. Systemic and local side effects of sublingual immunotherapy. *Clin Immunol.* 2010;Conference:2010.
148. Park JH, Yim BK, Lee JH, Lee S, Kim TH. Risk associated with bee venom therapy: a systematic review and meta-analysis. *PLoS ONE [Electronic Resource].* 2015;10:e0126971, 2015.
149. Passalacqua G. Specific immunotherapy: Beyond the clinical scores. *Annals of Allergy, Asthma and Immunology.* 2011;107:401.
150. Passalacqua G. Specific immunotherapy in asthma: a comprehensive review. *J Asthma.* 2014;51:29.
151. Passalacqua G, Compalati E, Canonica GW. Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper. *World Allergy Organiza.* 2010;journal. 3:216.
152. Passalacqua G, Compalati E, Canonica GW. Sublingual immunotherapy for allergic rhinitis: an update. *Current Opinion in Otolaryngology and Head and Neck Surgery.* 2011;19:43.

153. Passalacqua G, Garelli V, Sclifo F, Canonica GW. Sublingual immunotherapy for allergic rhinitis and conjunctivitis. *Immunotherapy*. 2013;5:257.
154. Passalacqua G, Rogkakou A, Mincarini M, Canonica GW. Allergen immunotherapy in asthma; what is new? *Asthma Research and Practice*. 2015;1.
155. Passalacqua GC. Sublingual Immunotherapy for Allergic Respiratory Diseases: Efficacy and Safety. *Immunol Allergy Clin North Am*. 2011;31:265.
156. Passalacqua GC. Specific immunotherapy in asthma: Efficacy and safety. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology*. 2011;41:1247.
157. Pfaar O, Demoly P, Wijk RGv, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. *Allergy*. 2014;69:854.
158. Pitsios C, Demoly P, Bilo MB, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. *Allergy*. 2015;70:897.
159. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). *Allergy*. 2011;66:740.
160. Ramsey S. Sublingual immunotherapy reduces symptoms of asthma and hay fever, systematic review finds. *BMJ*. 2056;346:f2056.
161. Ridolo E, Montagni M, Incorvaia C, Senna G, Passalacqua G. Orphan immunotherapies for allergic diseases. *Ann Allergy Asthma Immunol*. 2016;116:194.
162. Rizvi AY, Panchal AS. Timothy grass pollen allergen extract (Grastek) for allergic rhinitis. *Am Fam.Physician*. 2015;92:1096.
163. Roche AM, Wise SK. Subcutaneous immunotherapy. *Int Forum Allergy Rhinol*. 2014;4 Suppl 2:S51.
164. Ronborg SM, Svendsen UG, Micheelsen JS, Ytte L, Andreasen JN, Ehlers L. Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis. *ClinicoEcon*. 2012;outcomes res.. 4:253-60, 2012.
165. Ronborg SS. A comparative health economic evaluation of the SQ-standardised grass allergy immunotherapy tablet and subcutaneous immunotherapy in the treatment of grass pollen induced allergic rhinoconjunctivitis. *Allergy: European Journal of Allergy and Clinical Immunology*. 2011;Conference:June.
166. Rosa ML, Lionetti E, Leonardi S, et al. Specific immunotherapy in children: the evidence. 2011;24:69.
167. Saglani S. Allergen immunotherapy is useful in the treatment of childhood asthma (con). *Pediatric Pulmonology*. 2014;Conference:September.
168. Scala G. Real-life approach to allergen immunotherapy for respiratory diseases in childhood. *European Annals of Allergy and Clinical Immunology*. 2013;45:187.
169. Scaparrotta A, Attanasi M, Petrosino MI, Filippo PD, Pillo SD, Chiarelli F. Critical appraisal of Timothy grass pollen extract GRAZAX in the management of allergic rhinitis. *Drug design, development & therapy*. 2015;9:5897.
170. Schaffer FMG. The efficacy of the united allergy services selfadministered immunotherapy protocol. *Annals of Allergy, Asthma and Immunology*. 2014;Conference:A98.
171. Schaffer MFN. The safety and efficacy of a home-based self-administered immunotherapy protocol for pre-selected low risk patients. *Allergy: European Journal of Allergy and Clinical Immunology*. 2014;Conference:September.
172. Shin S, Song HJ, Park SY, et al. Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma. 2011.
173. Sieber J, Koberlein J, Mosges R. Sublingual immunotherapy in daily medical practice: effectiveness of different treatment schedules - IPD meta-analysis. *Current Medical Research & Opinion*. 2010;26:925.
174. Sieber J, Shah-Hosseini K, Mosges R. Specific immunotherapy for allergic rhinitis to grass and tree pollens in daily medical practice-symptom load with sublingual immunotherapy compared to subcutaneous immunotherapy. *Ann Med*. 2011;43:418.
175. Simons FER, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. *World Allergy Organization Journal*. 2015;8.
176. Slavyanakaya TA, Derkach VV, Sepiashvili RI. Debates in allergy medicine: specific immunotherapy efficiency in children with atopic dermatitis. *World Allergy Organization Journal*. 2016;9:15.
177. Solelhac GC. Management of allergic rhinitis. *F1000Prime Reports*. 1994;6:94.
178. Sopo SM, Battista A, Greco M, Monaco S. Grass pollen sublingual immunotherapy and paediatric allergic rhinitis: A patient-oriented decision. *Allergol Immunopathol (Madr)*. 2016;44:382.

179. Steinke JWL. T-cell biology in immunotherapy. *Annals of Allergy, Asthma and Immunology*. 2014;112:195.
180. Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. *J Allergy Clin Immunol Pract*. 2014;2:332.
181. Tsilochristou OAD. Pediatric allergic rhinitis and asthma: Can the march be halted? *Pediatric Drugs*. 2013;15:431.
182. Valero AW. Impact of allergen immunotherapy on quality of life and healthcare costs in patients with grass pollen-induced allergic rhinitis in Spain. *Allergy: European Journal of Allergy and Clinical Immunology*. 2014;Conference:September.
183. Valero AW. Cost-effectiveness analysis of allergen immunotherapy in patients with grass pollen-induced allergic rhinitis in Spain. *Value in Health*. 2014;Conference:A598.
184. Verheggen BG, Westerhout KY, Schreder CH, Augustin M. Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. *Clin Transl Allergy*. 2015;5:1, 2015.
185. Viswanathan RK, Busse WW. Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses. *Chest*. 2012;141:1303.
186. Vitaliti GP. Sublingual immunotherapy in preschool children: An update. *Expert Review of Clinical Immunology*. 2013;9:385.
187. Wahn U. Allergen immunotherapy is useful in the treatment of childhood asthma. *Pediatric Pulmonology*. 2014;Conference:September.
188. Wahn U, Passalacqua G, Sastre J, Demoly P. Use of 300IR house dust mite sublingual immunotherapy in pediatric respiratory allergy: A critical appraisal of published data. *Allergy: European Journal of Allergy and Clinical Immunology.Conference: 35th Annual Congress of the European Academy of Allergy and Clinical Immunology, EAACI 2016.Austria.Conference Start: 20160611.Conference End: 20160615.71 ()(pp 336), 2016.Date*. 2016:336.
189. Walker SM, Durham SR, Till SJ, et al. Immunotherapy for allergic rhinitis. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology*. 2011;41:1177.
190. Wang C, Zhang L. Specific immunotherapy for allergic rhinitis in children. *Current Opinion in Otolaryngology and Head and Neck Surgery*. 2014;22:487.
191. Watanabe AS, Fonseca LA, Galvao CE, Kalil J, Castro FF. Specific immunotherapy using Hymenoptera venom: systematic review. *Sao Paulo Med J*. 2010;128:30.
192. Westerhout KY. Cost-effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinitis. *Value in Health*. 2011;Conference:A494.
193. Westerhout KY, Verheggen BG, Schreder CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. *J Med Econ*. 2012;15:906.
194. Wise SK, Schlosser RJ. Evidence-based practice: sublingual immunotherapy for allergic rhinitis. *Otolaryngol Clin North Am*. 2012;45:1045.
195. Wise SK, Schlosser RJ. Subcutaneous and sublingual immunotherapy for allergic rhinitis: what is the evidence? *Am J Rhinol Allergy*. 2012;26:18.
196. Yukselen A. Allergen-specific immunotherapy in pediatric allergic asthma. *Asia Pacific Allergy*. 2016;6:139.
197. Yukselen A, Kendirli SG. Role of immunotherapy in the treatment of allergic asthma. *World Journal of Clinical Cases*. 2014;2:859.